Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 58

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 1
Chunk 58
---
 million decrease in operating expenses due primarily to lower administrative costs of $8.5 million due primarily to Project Energize. This decrease was partially offset by higher advertising and promotion investments and higher restructuring costs compared to the prior year.

CONSUMER SELF-CARE INTERNATIONAL FINANCIAL RESULTS

 Three Months Ended(in millions, except percentages)March 29, 2025March 30, 2024Net sales$423.1 $437.9 Gross profit$192.2 $204.2 Gross profit %45.4 %46.6 %Operating income$39.6 $26.5 Operating income %9.4 %6.1 %

Net sales decreased $14.8 million, or 3.4%, due primarily to: 

•$21.3 million decrease due to the prior year divestitures of the Rare Diseases and Hospital and Specialty Businesses and the sale of branded products;

•$12.2 million decrease from unfavorable foreign currency translation; partially offset by

•$18.7 million increase, or 4.5%, due primarily to higher net sales of $11.4 million in the Upper Respiratory and Pain and Sleep-Aids categories, due primarily to higher incidence levels of cough cold compared to the prior year period and improved supply of key products, as well as higher net sales of $4.9 million in the Healthy Lifestyle category led by strong momentum in smoking cessation brand NiQuitin®, and $2.7 million from the Skin Care category led by brands Compeed® and Sebamed®, and earlier customer purchases ahead of the spring/summer season compared to the prior year period.

43

Perrigo Company plc - Item 2CSCI

CSCI net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)March 29, 2025March 30, 2024$ Change% ChangeSkin Care$111.5 $114.7 $(3.2)(2.8)%Upper Respiratory73.5 69.1 4.4 6.4 %Healthy Lifestyle66.6 64.6 2.0 3.1 %Pain and Sleep-Aids53.6 51.4 2.2 4.3 %VMS37.7 44.6 (6.9)(15.5)%Women's Health32.4 32.0 0.